Clindamycin does not cover aerobic gram-negative bacteria, which is one of the most important gaps in its spectrum. It does have activity against certain gram-negative anaerobes, but even that coverage has become less reliable as resistance rates climb. If you’re trying to understand what clindamycin actually treats and where it falls short, the distinction between aerobic and anaerobic gram-negative organisms is the key.
What Clindamycin Covers
Clindamycin works by interfering with bacterial protein synthesis. It binds to the large subunit of the bacterial ribosome and blocks the machinery bacteria need to build proteins, which either kills them or stops their growth depending on the concentration.
Its strongest coverage is against gram-positive organisms: staphylococci (including many MRSA strains), streptococci, and other common gram-positive bacteria. It also covers many anaerobic bacteria, which are organisms that thrive in low-oxygen environments like deep wounds, abscesses, and the gut. This anaerobic activity is where some gram-negative coverage comes in, but it’s limited to specific species.
Gram-Negative Anaerobes: Partial Coverage
Clindamycin has meaningful activity against a handful of gram-negative anaerobic species. It’s considered a first-line option for Prevotella melaninogenicus, Prevotella intermedius, and Fusobacterium necrophorum. These are bacteria commonly found in oral, respiratory, and pelvic infections. In lab testing, Fusobacterium strains tend to be reliably susceptible.
For the Bacteroides group, which includes Bacteroides fragilis and several related species, clindamycin is only a second-line option. This matters because B. fragilis is one of the most clinically significant gram-negative anaerobes, frequently involved in abdominal and pelvic infections. In one large susceptibility study, about 78% of B. fragilis isolates were susceptible to clindamycin, meaning roughly 1 in 5 were already resistant. For Prevotella and Fusobacterium species in the same study, susceptibility to clindamycin was higher, around 88%.
No Activity Against Aerobic Gram-Negatives
The organisms most people think of as “gram-negative bacteria” are the aerobic ones: E. coli, Klebsiella, Pseudomonas, Proteus, Salmonella, and similar species. Clindamycin has zero useful activity against any of these. If an infection involves aerobic gram-negative rods, clindamycin alone will not treat it. This is not a resistance problem or a dosing issue. The drug simply does not work against this entire category of bacteria.
This gap is the reason clindamycin is so often paired with another antibiotic when broader coverage is needed. In pelvic inflammatory disease, for example, the CDC lists clindamycin plus gentamicin as one of the recommended inpatient regimens. Clindamycin handles the anaerobes and gram-positive organisms, while gentamicin covers the aerobic gram-negative bacteria like E. coli that are also involved. Neither drug alone would be sufficient.
Rising Resistance in Bacteroides
Even the gram-negative anaerobic coverage clindamycin does provide has been eroding. Resistance rates among B. fragilis now range from 20% to 40% in North America and Europe, and reach approximately 50% in parts of Asia. A multicenter study found clindamycin resistance at 38.2% in B. fragilis isolates, with even higher rates (59.7%) in non-fragilis Bacteroides species.
These resistance rates have remained fairly stable rather than declining, which means the problem isn’t temporary. For serious intra-abdominal infections where Bacteroides species are likely involved, many clinicians now prefer metronidazole or certain beta-lactam combinations, which maintain susceptibility rates above 95% against these organisms.
Where Clindamycin’s Strengths Lie
Despite its gram-negative limitations, clindamycin has some useful properties that keep it relevant. It penetrates bone and abscesses well, which many antibiotics struggle to do. It also gets taken up by immune cells called phagocytes, which carry it directly to sites of inflammation and infection. It distributes well into most body fluids, with the notable exception of cerebrospinal fluid.
These properties make clindamycin valuable for skin and soft tissue infections, bone infections, dental infections, and certain lung abscesses, particularly when gram-positive bacteria and oral anaerobes are the primary concern. For mixed infections that also involve aerobic gram-negative organisms, a second antibiotic with gram-negative activity needs to be added. Clindamycin is not, and has never been, a broad-spectrum drug that covers both sides of the gram stain on its own.